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A yeast expression plasmid encoding a mini-proinsulin molecule was constructed and transformed into Sac- 
charomyces cerevisiae. The plasmid encoded the sequence: B-Arg-Arg-Leu-Gln-Lys-Arg-A in which B repre- 
sents the B-chain (30 amino acid residues) and A represents the A-chain (21 amino acid residues) of human 
insulin. The secreted peptides were shown to be a mixture of human insulin and des(B-30)human insulin. 
Thus, correct disulphide bridges can be established in proinsulin-like molecules devoid of a normal C-pep- 
tide region. Furthermore, the specificity of the yeast processing enzymes is so similar to the proinsulin con- 
verting enzymes in the human pancreatic ~-cell that it allows the processing of the mini-proinsulin to insulin. 
Proinsulin; C-peptide; Processing; Dibasic sequence; Hormone precursor 
1. INTRODUCTION 
Secreted peptide pheromones are triggers which 
are necessary to initiate mating between haploid 
cells of Saccharomyces cerevisiae [ 11. One 
pheromone, the a-factor, is a peptide of 13 amino 
acid residues [2] which is synthesized in the yeast 
cells as a high molecular mass precursor [3]. The 
sequencing of the mating factor cyl precursor gene 
(MFal) revealed that the a-factor is present in four 
repeats separated by spacer peptides with the se- 
quences of Lys-Arg-(Glu-Ala)3 or Lys-Arg-Glu- 
Ala-Asp-Ala-Glu-Ala [3]. The posttranslational 
processing of the precursor includes trypsin-like 
cleavages at Lys-Arg sequences and dipeptidyl 
aminopeptidase-like cleavages for the removal of 
the Glu-Ala and Asp-Ala sequences [4]. 
In the pancreatic &cell of mammals a similar en- 
zyme system is responsible for the posttransla- 
tional processing of proinsulin to insulin (for 
review see Steiner et al. [5]). We have previously 
studied the secretion and processing in yeast of a 
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series of insulin precursors containing one or two 
dibasic sequences [6]. These studies revealed that 
proinsulin is rapidly cleaved at one or both dibasic 
sequences and that these cleavages to a large extent 
occur before disulphide bond formation. 
However, when the C-peptide of 31 amino acid 
residues was replaced by a spacer peptide of two 
amino acid residues (Leu-Gln), a higher amount of 
insulin-like peptides was secreted [6]. The present 
study was undertaken in order to determine the ex- 
act structure of the insulin-like peptides ecreted by 
a transformed yeast encoding this mini-proinsulin 
molecule. From the structural studies the pattern 
of posttranslational processing could be deduced 
and the similarity between the yeast processing en- 
zyme system and the proinsulin-converting enzyme 
system could be further elucidated. 
2. MATERIALS AND METHODS 
2.1. Plasmid construction 
The yeast expression plasmid encoding the mini- 
proinsulin sequence has been described in detail 
elsewhere [6]. Briefly the gene encoding the first 85 
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amino acid residues of the yeast mating factor (~1 
(MFal) leader sequence [4] was fused to the mini- 
proinsulin encoding gene in the configuration: 
MFal(l-83)-Lys-Arg-B-Arg-Arg-Leu-Gln-Lys- 
Arg-A in which B and A represent he B-chain and 
A-chain of human insulin. This const~ction was 
inserted between the promoter and the transcrip- 
tion termination regions of the triose phosphate 
isomerase gene of S. cerevisiue and the entire ex- 
pression unit was inserted in plasmid CPOT [7], 
which was transformed into a triose phosphate 
isomerase deficient strain of S. cerevisiae [6]. 
2.2. Peptide purificuti~n 
The transformed yeast strain was grown on a 
YPD medium [8] to an optical density at 660 nm of 
9.0 (37”C, 72 h). The yeast culture was centrifuged 
and 150 ml of ethanol was added to 1.5 1 of yeast 
supernatant. The solution was passed through a 
column (2.6 x 4.0 cm) of LiChroprep RP-18, 
25-40 pm (Merck) at a flow rate of 100 ml/h. The 
column was washed with 50 ml of 0.1 M NaCl 
followed by 50 ml of water and the peptide 
material was eluted with 60% (v/v) ethanol in 
50 mM ammonium hydrogencarbonate. The 
eluate was concentrated to 5 ml by vacuum cen- 
trifugation to remove the ethanol, and the volume 
was adjusted to 10 ml by the addition of 5 ml of 
50 mM Hepes buffer (pH 7.4). The sample was ap- 
plied to an anti-insulin Sepharose column (2.5 x 
4.5 cm) equilibrated in 25 mM Hepes buffer (pH 
7.4). Anti-insulin Sepharose was prepared by 
coupling of monoclonal insulin antibody (MCA 
OX1 001, Novo Industri A/S) to CNBr-activated 
Sepharose (Pharmacia) as described by the 
manufacturer (5 mg/ml gel). The column was 
allowed to stand for 30 min at room temperature 
and washed with 40 ml of 25 mM Hepes buffer 
(pH 7.4). Peptide material was eluted with 10% 
(v/v) acetic acid and the pH of the eluate was ad- 
justed to 4.0 with 2 N NaOH. The peptide material 
was finally purified by HPLC on a Macherey- 
Nagel 5 pm Nucleosil RP C-18 column (4 x 
200 mm) equilibrated and isocratically eluted with 
33 mM ammonium sulphate, 1.5 mM sulphuric 
acid cont~ning 29.4% (v/v) acetonitrile at 30°C at 
a flow rate of 1 mllmin (fig.lA). Peptides were 
detected by measurement of absorption at 214 nm. 
The yields of peptides 1 and 2 (fig.lA) as deter- 
mined by HPLC were 540 and 590 pug, respectively. 
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2.3. Sequence analysis 
Edman degradation of peptides 1 and 2 was per- 
formed with an Applied Biosystems model 470A 
gas-phase sequencer [9] with some modifications. 
A fourth solvent (Sl = n-heptane) was included for 
washing of the filter for 0.5 min after coupling 
with phenylisothiocyanate. The conversion was 
carried out with 25% (v/v) trifluoroacetic acid. 
The phenylthiohydantoin amino acids (PTH-aa) 
were dissolved in 0.25 ml of methanol/acetonitrile 
(50:50, v/v) and dried in a Savant vacuum cen- 
trifuge for 10 min at 45°C. Dried PTH-aa were 
redissolved in 25 pl of acetonitrile containing 
methylthiohydantoin-tryptoph~ as internal stan- 
dard. The PTH-aa were identified and quantified 
by reverse-phase HPLC on an Applied Biosystems 
PTH C-18 microbore column (2.1 x 220 mm) as 
described by the manufacturer. The column was 
mounted in a Hewlett-Packard liquid chroma- 
tograph model 1090 equipped with a pro- 
grammable filter-photometer for detection at 263 
and 314 nm (dehydro-derivatives of Ser and Thr). 
The detection limit of PTH-aa was 0.5 pmol. 
2.4. Peptide mapping 
Samples of yeast peptides 1 and 2 corresponding 
to 16 ,ug were dissolved in 200 pl of 50 mM Tris- 
HCl buffer (pH 7.4) containing 25 mM of 
N&EDTA. A solution of 10,ul of subtilisin A 
(Novo Industri A/S) containing 0.5 pglpl in 
50 mM Tris-HCl buffer (pH 7.4) was added. This 
corresponds to an enzyme to substrate ratio of 
1: 16, mol/mol. The digestions were carried out at 
37°C for 18 h. Standards of human insulin and 
des(B-30)human i sulin (Novo Industri A/S) were 
digested under the same conditions. The peptide 
mapping was carried out by the injection of 10~1 
of the above digest mixtures onto a Macherey- 
Nagel 5 /cm Nucleosil RP C-18 column (4 x 
200 mm). The A and B buffers were 5% 
acetonitrile in 1.5 mM sulphuric acid and 45% 
acetonitrile in 1.5 mM sulphuric acid containing 
0.15 M ammonium sulphate. The column was 
eluted with 5% B for 4 min and thereafter with a 
linear gradient o 45% B over 20 min at a flow rate 
of 1 ml/min at 30°C. Peptides were detected by 
measuring the absorption at 214 nm (fig.2). 
2.5. Assay for insulin 
Yeast peptides 1 and 2 were analyzed in a free fat 
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cell bioassay for insulin as described by Moody et 
al. [lo] with the exception that the fat cells were 
taken from mice instead of from rats. In this type 
of assay, des(B-30)insulin has a potency of approx. 
100% whereas otherwise modified insulins have a 
significantly reduced potency [ 11). The potency of, 
des(A-21)insulin desoctapeptide- 
tB&-30)insulin is less than % [l 11. 
A 
3. RESULTS 
3.1. Purification of secreted peptides 
The scheme used in the present study to purify 
insulin-like peptides from the fermentation broth 
consisted of three steps. The initial step was carried 
out mainly to concentrate the peptide material in 
the yeast culture supernatant. The subsequent im- 
munoaffinity step on the anti-insulin Sepharose 
column retained only insulin-like peptides, which 
were finally purified in the HPLC step. Insulin-like 
molecules with e.g. incorrect disulphide bridges, or 
various insulin degradation products would not be 
absorbed on the immunoaffinity column. By the 
addition of “‘I-insulin (Novo Industri A/S) to the 
yeast supernatant, the yields in the different steps 
of the purification were found to be: 89% 
(LiChroprep RP-18 column), 95% (anti-insulin 
Sepharose column) and 70% (HPLC) corre- 
sponding to an overall yield of 59%. The eluate 
from the anti-insulin Sepharose column was found 
to contain two major insulin-like peptides (pep- 
tides 1 and 2, fig.lA), and three minor com- 
ponents. Only the peptides corresponding to the 
two major peaks were further characterized. 
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By HPLC analysis peptide 1 was found to 
coelute with a standard of human insulin (fig.lB) 
and peptide 2 was found to coelute with a standard 
of des(B-30)human insulin (fig. 1C). Fig. ID shows 
the HPLC chromatogram obtained by the analysis 
of a mixture of the human insulin and 
des(B-30)human insulin standards. 
Fig.1. HPLC traces showing the coelution of yeast 
peptide 1 with human insulin and yeast peptide 2 with 
des(B-30)human insulin. Panel A, anti-insulin Sepharose 
eluate. Peptides 1 and 2 elute at the retention times of 
24.01 and 25.38 min, respectively. Panel B, anti-insulin 
Sepharose eluate after the addition of 1 pg of human 
insulin. Panel C, anti-insulin Sepharose elutes after the 
addition of 1 pg of des(B-30)human insulin. Panel D, a 
standard mixture of 1 pg of human insulin and 1 yg of 
des(B-30)human insulin. All chromatograms were 
obtained under isocratic conditions (29.4% of 
acetonitrile). 
3.2. Structure analysis 
The results from the automated Edman degrada- and 2 was performed after digestion with subtilisin 
tion of yeast peptides 1 and 2 are shown in table 1. A, and the peptide maps were compared with those 
Both peptides were found to be two chain obtained from standards of human insulin and 
molecules. The amino acid sequences of peptides 1 des(B-30)human i sulin under the same conditions 
and 2 were found to be identical to those of human (fig.2). These analyses establish that the disulphide 
insulin and des(B-30)human insulin, respectively. bond configurations in the two yeast peptides are 
In addition, peptide mapping of yeast peptides 1 identical to those of insulin. 
309 
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Table 1 
Automated Edman degradation of peptides 1 and 2a 
Cycle 
no. 
Peptide 1 Peptide 2 
PTH-aa Yield PTH-aa Yield PTH-aa Yield PTH-aa Yield 
(pmol) (pmol) Cpmol) (pmoIf 
1688 
1302 
1023 
783 
483 
1068 
1 Phe 
2 Val 
3 Asn 
4 Gln 
5 His 
6 Leu 
7 (CYS)’ _ 
8 GlY 122 
9 Ser ( 105)b 
10 His 373 
11 Leu _ 
12 Val 75 
13 Glu 278 
14 Ala 232 
15 Leu 176 
16 Tyr 329 
17 Leu 201 
18 Val 162 
19 (CYS)’ 174 
20 Gly - 
21 Glu 101 
22 Arg 
23 GIY 
24 Phe 
25 Phe 
26 Tyr 
27 Thr 
28 Pro 
29 LYS 
30 Thr 
a Average repetitive yield: 91 .O% (peptide A), 90.5% (peptide B) 
b Ser is present in both chains 
’ Cys is not determined by sequence analysis 
GIY 
Be 
Val 
GlU 
Gln 
(CYS)” 
(Cus)’ 
Thr 
Ser 
Be 
(CYS)” 
Ser 
Leu 
Tyr 
Gln 
Leu 
Glu 
Asn 
Tyr 
(CYS)’ 
Am 
1314 
1218 
1338 
1381 
957 
_ 
_ 
672 
(105)b 
401 
577 
537 
696 
492 
592 
509 
629 
413 
284 
380 
199 
179 
119 
154 
133 
23 
39 
33 
15 
Phe 
Val 
Asn 
Gln 
His 
Leu 
(Qs)’ 
GIY 
Ser 
His 
Leu 
Val 
Ghl 
Ala 
Leu 
Tyr 
Leu 
Val 
(CYS)’ 
GIY 
Glu 
Arg 
GIY 
Phe 
Phe 
Tyr 
Thr 
Pro 
LYS 
156 
152 
318 
144 
61 
103 
- 
(Z)b 
48 
66 
52 
59 
57 
80 
46 
82 
51 
- 
43 
39 
26 
35 
25 
31 
15 
9 
9 
6 
GIY 
Be 
Val 
Glu 
Gln 
(CYS)’ 
(CYS)” 
Thr 
Ser 
Ile 
(CYS)’ 
Ser 
Leu 
Tyr 
Gln 
Leu 
Glu 
Asn 
Tyr 
(cYs)C 
Asn 
165 
187 
196 
238 
162 
- 
(&b 
32 
- 
13 
31 
22 
21 
46 
27 
trace 
11 
- 
trace 
From the results obtained by peptide mapping 
(fig.2), by sequence analysis (table 1) and by 
HPLC analysis (fig.l), it is concluded that yeast 
peptide 1 is identical to human insulin and yeast 
peptide 2 is identical to des(B-30)human insulin. 
3.3. Eidogical activity 
The biological potency of yeast peptides 1 as 
determined in the free fat cell assay was 97010 (P < 
0.05, confidence limit 93-102%) as compared to a 
human insulin standard (defined as 100%). When 
compared to a des(B-30)human insulin standard, 
yeast peptide 2 had a potency of 101% (P c 0.05, 
confidence limit 96-106%). These results are in 
agreement with the potency obtained by use of the 
corresponding pancreatic peptides 1111. 
4. DISCUSSION 
In the present study the gene encoding the mini- 
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Fig.2. Peptide maps after digestion of peptides with subtilisin. Panels: A, yeast peptide 1; B, human insulin; C, yeast 
peptide 2; D, des(B-30)human insulin. 
proinsulin molecule: B-Lys-Arg-Leu-Gln-Arg- 
Arg-A was transformed into S. cerevisiae. Two 
peptides were isolated in approximately equal 
amounts from the culture supernatant of the 
transformed yeast strain. By structural analysis as 
well as by biological activity the peptides were 
identified as human insulin and des(B-30)human 
insulin. We have previously detected only minor 
amounts of disulphide bridge-linked molecules 
secreted from yeast cells in which the intact proin- 
sulin encoding gene had been inserted 161. Thus, 
correct in vivo folding and disulphide bond forma- 
tion seem to occur more easily in the mini- 
proinsulin molecule than in the intact proinsulin 
molecule. Furthermore, the rate of folding and 
disulphide bond formation in the mini-proinsulin 
molecule is sufficiently high to prevent extensive 
premature processing and consequent separation 
of the B-chain from the A-chain. Several insulin 
precursors containing a short peptide link between 
amino acids B-30 and A-l were recently expressed 
and secreted from transformed yeast cells [6,12]. 
These types of molecules, e.g. B(l-29)~Ser-Lys- 
A(l-21) [12] and B(l-30)-Lys-Arg-All-21) [6], 
can be isolated as single-chained, disulphide 
bridge-linked molecules from the yeast culture 
supernatant. The single chain nature of these 
molecules is due either to the absence of processing 
sites between the B- and A-chains, or, when such 
sites are present, the single chain nature has been 
taken as evidence of the inaccessibility of the sites 
to the yeast processing enzyme system [6]. The pre- 
sent study shows that a short spacer peptide 
flanked by dibasic sequences placed between the B- 
and A-chains results in a precursor molecule 
which, in addition to its rapid folding, carries its 
proteolytic processing sites in a configuration suf- 
ficiently exposed to allow the in vivo conversion in- 
to two chain insulin. The processing in yeast of the 
Lys-Arg and Arg-Arg sequences of the mini- 
proinsulin molecule is most probably carried out 
by the Lys-Arg specific endopeptidase of S. 
cerevisiae, the KEX 2 gene product [13]. 
The generation of des(B-3O)human i sulin could 
be a result either of a trypsin-like cleavage after 
B-29 Lys or of a carboxypeptidase-like r moval of 
311 
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B-30 Thr. It has previously been shown that the 
Lys-Arg processing enzyme in yeast does not 
cleave after single basic amino acid residues [14], 
and a membrane-bound carboxypeptidase possibly 
involved in the removal of Lys and Arg during a- 
factor processing has been identified [ 141. We find 
it therefore most likely that the membrane-bound 
carboxypeptidase is responsible for the removal of 
B-30 Thr. The reason for the enzyme not to 
remove B-29 Lys as well might be caused by the 
presence of Pro in position B-28. 
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